Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study (Q34747015)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

George Fountzilas

13

object named as

George Fountzilas

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

author name string

Evangelos Briasoulis

1

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Gerasimos Aravantinos

2

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

George Kouvatseas

3

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Periklis Pappas

4

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Eirini Biziota

5

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Ioannis Sainis

6

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Thomas Makatsoris

7

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Ioannis Varthalitis

8

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Ioannis Xanthakis

9

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Antonios Vassias

10

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

George Klouvas

11

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Ioannis Boukovinas

12

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Kostantinos N Syrigos

14

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Haralambos Kalofonos

15

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Epaminontas Samantas

16

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

language of work or name

0 references

publication date

29 May 2013

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

263

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Overcoming resistance to antiangiogenic therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674943

7 July 2018

Salvage therapy with oral metronomic cyclophosphamide and methotrexate for castration-refractory metastatic adenocarcinoma of the prostate resistant to docetaxel

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674943

7 July 2018

Metronomic scheduling of anticancer treatment: the next generation of multitarget therapy?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674943

7 July 2018

Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674943

7 July 2018

Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674943

7 July 2018

Metronomic chemotherapy: new rationale for new directions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674943

7 July 2018

Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674943

7 July 2018

Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674943

7 July 2018

Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674943

7 July 2018

Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674943

7 July 2018

A history of cancer chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674943

7 July 2018

Progress in cancer care: the hope, the hype, and the gap between reality and perception

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674943

7 July 2018

Modes of resistance to anti-angiogenic therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674943

7 July 2018

VEGF-targeted therapy: mechanisms of anti-tumour activity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674943

7 July 2018

Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674943

7 July 2018

Angiogenesis: an organizing principle for drug discovery?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674943

7 July 2018

Metronomic chemotherapy: an antiangiogenic scheduling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674943

7 July 2018

The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674943

7 July 2018

Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674943

7 July 2018

The anti-angiogenic basis of metronomic chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674943

7 July 2018

Tie2/Tek expression in breast carcinoma: correlations of immunohistochemical assays and long-term follow-up in a series of 909 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674943

7 July 2018

Metronomic scheduling: the future of chemotherapy?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674943

7 July 2018

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674943

7 July 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674943

7 July 2018

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674943

7 July 2018

In vitro hematopoietic and endothelial cell development from cells expressing TEK receptor in murine aorta-gonad-mesonephros region

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674943

7 July 2018

tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674943

7 July 2018

Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-263

21 January 2018

Clinical Application of Therapies Targeting VEGF

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-263

21 January 2018

Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-263

21 January 2018

Can a rational design for metronomic chemotherapy dosing be devised?

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-263

21 January 2018

Reporting recommendations for tumor marker prognostic studies (REMARK).

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-263

21 January 2018

New sensitive liquid chromatography method coupled with tandem mass spectrometric detection for the clinical analysis of vinorelbine and its metabolites in blood, plasma, urine and faeces

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-263

21 January 2018

Dose-finding based on efficacy-toxicity trade-offs

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-263

21 January 2018

Expression of angiogenic markers in the peripheral blood of docetaxel-treated advanced breast cancer patients: a Hellenic Cooperative Oncology Group (HeCOG) study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3674943

26 October 2018

Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG)

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-13-263

21 January 2018

Dose: a critical factor in cancer chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/23718900

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Continuous low-dose anti-angiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic

1 reference

https://pubmed.ncbi.nlm.nih.gov/23718900

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeted therapies: disappointing outcomes for anti-VEGF therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/23718900

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition

1 reference

https://pubmed.ncbi.nlm.nih.gov/23718900

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules

1 reference

https://pubmed.ncbi.nlm.nih.gov/23718900

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2407-13-263

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34747015&oldid=2197004588"